Genius Study Study to Compare Efficacy and Safety of Gefitinib/ Pemetrexed With Pemetrexed Alone as Maintenance Therapy in Patients With Stage IV EGFR Mutation Negative or T790M Single Mutation Who Respond to Pemetrexed/ Platinum as First-line Therapy

NCT01579630 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

52

Enrollment

OTHER_GOV

Sponsor class

Conditions

NSCLC

Interventions

DRUG: Pemetrexed 500mg/m2 iv
DRUG: Pemetrexed 500mg/m2 iv and Gefitinib 250 mg

Sponsor

Taipei Veterans General Hospital, Taiwan

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]